Trastuzumab Success Rate and Survival: — An Honest Look at the Numbers

There is no single success rate — the figure depends on stage, what trastuzumab is combined with, and individual tumour characteristics. In early HER2-positive breast cancer, trastuzumab-based regimens aim to prevent recurrence, and NCCN and ASCO guidelines document substantial benefit in reducing that risk. In metastatic disease, the aim is disease control rather than prevention, and outcomes vary more widely. Ask your oncologist which setting applies to you and what the relevant evidence shows for your specific situation.

In early-stage disease, trastuzumab is given for a defined course rather than indefinitely, and the question is whether it prevents recurrence rather than how long it keeps working. In metastatic disease, treatment continues until progression or side effects require a change, and how long that takes varies considerably between patients. Your oncologist assesses response with imaging at regular intervals and will have a plan for what happens next if and when progression occurs.

Both settings have evidence of benefit, but the goals differ. In early-stage cancer, the aim is to reduce recurrence risk after surgery, and ASCO and ESMO guidelines describe this as one of the most clearly established uses of the drug. In advanced or metastatic disease, the aim is to control the cancer and maintain quality of life. Neither setting guarantees a specific outcome — both represent the best current evidence for that situation. Your oncologist can explain which applies to you and what the specific intention of your treatment is.

After completing a standard course, you move to regular follow-up — clinic visits and imaging at intervals set by your oncologist. There is no additional maintenance drug in most standard regimens at this point, though in some higher-risk situations further targeted treatment may be recommended. Follow-up is active monitoring with a clear plan for what to do if anything changes. Ask your oncologist what your follow-up schedule will look like and what symptoms to report between appointments.

Several newer HER2-directed agents have been developed since trastuzumab was approved — including pertuzumab, trastuzumab emtansine, and trastuzumab deruxtecan. These are used in particular settings: some alongside trastuzumab, some as later lines of treatment, rather than replacing it outright. NCCN and ESMO guidelines incorporate these agents at different points in the treatment pathway. Which ones are relevant to you depends on your stage and prior treatment. Your oncologist will explain how they factor into your plan.

Three questions are worth writing down before your appointment. First: which published evidence applies most closely to my stage and regimen — not a general figure, but one that matches my situation? Second: what is the goal of this treatment — to prevent recurrence, to control the disease, or something else? Third: what would a good response look like, and how will we know whether it is happening? These three questions will produce more useful information than any survival figure found by searching online.